Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 12, 2007, Pages 2421-2428

  Meroni, Pier Luigi ^a,b,h   Peyvandi, F ^a,c   Foco, L ^d   Bernardinelli, L ^d,e   Fetiveau, R ^f   Mannucci, P M ^a,c   Tincani, A ^g  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f Hospital of Legnano   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h Ospedale San Luca   (Italy)

Author keywords

Anti beta2 glycoprotein I antibodies; Anti phospholipid antibodies; Myocardial infarction; Premenopausal women

Indexed keywords

ACETYLSALICYLIC ACID; ANTI BETA2 GLYCOPROTEIN 1 ANTIBODY; ANTINUCLEAR ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COCAINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ANGIOCARDIOGRAPHY; ANTIBODY BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HEART INFARCTION; HORMONE DEFICIENCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT SELECTION; PHYSICAL MOBILITY; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SUBSTANCE ABUSE;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ITALY; MYOCARDIAL INFARCTION; ODDS RATIO; PREMENOPAUSE; RISK ASSESSMENT; RISK FACTORS;

EID: 36348974558     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02763.x     Document Type: Article

References (43)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
2. Galli M, Borrelli G, Jacobsen EV, Marfisi RM, Finazzi G, Marchioli R, Wisloff F, Marziali S, Morboeuf O, Barbui T. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-83.
3. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
4. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-5.
5. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation1995; 91: 23-7.
6. Espinosa G, Cervera R, Font J, Garcia-Carrasco M, Battagliotti C, Ingelmo M. Cardiac and pulmonary manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The Antiphospholipid Syndrome. Amsterdam: Elsevier Science BV, 2002: 169-88.
7. Font J, Cervera R. Cardiac manifestations in antiphospholipid syndrome. In: Khamashta MA, ed. Hughes Syndrome. London: Springer-Verlag, 2006: 41-52.
8. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
9. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654-61.
10. Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: Risk factors and clinical features. J Emerg Med 1996; 14: 139-45.
11. Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364-9.
12. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P., Stamler R, Neaton JD. Low risk-factor profile and long-term cardiovascular and non-cardiovascular mortality and life expectancy: Findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012-8.
13. Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999; 107: 254-61.
14. Mukherjee D, Hsu A, Moliterno DJ, Lincoff AM, Goormastic M, Topol EJ. Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or= 40 years old. Am J Cardiol 2003; 92: 1465-7.
15. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP, APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
16. Brey RL. Management of the neurological manifestations of APS - what do the trials tell us? Thromb Res 2004; 114: 489-99.
17. Lockshin M. Sex differences in autoimmune disease. Lupus 2006; 15: 753-6.
18. Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-22.
19. Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gilburd B, Heide KG, Hoier-Madsen M, Meroni PL, Monier JC, Monneret G, Panzeri P, Shoenfeld Y, Spertini F, Wiik A. Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun 1999; 13: 89-93.
20. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anti-cardiolipin antibody assay: A methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
21. Meroni PL, Mari D, Monti D, Coppola R, Capri M, Salvioli S, Tincani A, Gerli R, Franceschi C. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp Gerontol 2004; 39: 1459-65.
22. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa MC, Arvieux J. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
23. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC; Standardization Group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2: 1860-2.
24. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, Boffa MC. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-8.
25. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of antinuclear antibodies in "healthy"individuals. Arthritis Rheum 1997; 40: 1601-11.
26. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149: 1063-8.
27. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
28. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: Basic mechanisms. Rheum Dis Clin North Am 2005; 31: 355-62.
29. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004; 112: 169-74.
30. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32: 537-51.
31. Jimenez S, Garcia-Criado MA, Tassies D, Reverter JC, Cervera R, Gilabert MR, Zambon D, Ros E, Bru C, Font J. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005; 44: 756-61.
32. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: Preliminary data. Ann Rheum Dis 2005; 64: 315-7.
33. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003; 349: 2407-15.
34. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
35. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351: 260-7.
36. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-5.
37. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3918-25.
38. Hulstein JJJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG. Beta2-glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood 2007; 110: 1485-91.
39. Dunoyer-Geindre S, Kwak BR, Pelli G, Roth I, Satta N, Fish RJ, Reber G, Mach F, Kruithof EK, de Moerloose P. Immunization of LDL receptor-deficient mice with β(2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. Thromb Haemost 2007; 97: 129-38.
40. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anti-cardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101: 1827-32.
41. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
42. Ranzolin A, Bohn JM, Norman GL, Manenti E, Bodanese LC, von Muhlen CA, Staub HL. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol 2004; 83: 141-4; 137-40.
43. Tincani A, Franceschini F, Spunghi M, Panzeri P, Balestrieri G, Meroni PL. Immunological abnormalities in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The Antiphospholipid Syndrome. Amsterdam: Elsevier Science BV, 2002: 271-83.